Recombinant IL-6 and TGFβ1 were used at functionally effective doses to model the neuroblastoma/monocyte generated molecules to study the effects of these cytokines individually without or with lenalidomide upon NK cell activation. Here, TGFB1 is linked to neuroblastoma.